Using comprehensive genomic and immune profiling on discovery cohort of 24,186 solid tumors across 35 tumor types, this study confirmed that TIGIT expression is correlated with PD-L1 expression. Patients whose tumors express higher levels of TIGIT and PD-L1 via immunohistochemistry had improved overall survival.

This study validated an automated, scalable comprehensive genomic profiling assay this with an expanded gene panel of 141 genes in 293 patients with hematologic malignancies for the detection of clinically informative genomic alterations.

AACR 2024 -- Monoclonal antibodies (mAbs) that target tumor antigen have transformed cancer immunotherapy. Antibody-dependent cellular cytotoxicity (ADCC) is an indispensable therapeutic mechanism for mAbs, including antibody-drug conjugates, because they trigger immune-mediated antitumor activity in vivo.

AACR 2024 -- Traditional cancer cell lines used as surrogate models in vitro and in vivo have made significant contributions to cancer research and drug discovery.

AACR 2024 -- Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising approach for treating hematological malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL).

AACR 2024 -- The failure of murine tumor models to adequately simulate the native biological milieu and tissue architecture of human malignancies, has fomented much discourse surrounding the exigencies of bench to bedside translation.

AACR 2024 -- The tumor microenvironment consists of various components such as cancer-associated fibroblasts, immune cells, blood vessels and extracellular matrix elements, all of which have the potential to interact with cancer cells.

AACR 2024 -- Immunotherapy aims to bolster the immune response within the tumor microenvironment (TME). However, checkpoint inhibitors utilized in the treatment of colon carcinoma have demonstrated efficacy only in certain patients.